Another One: FDA Expects to Authorize 6th mRNA Dose in the Fall

“I don’t want to shock anyone, but there may be a need for people to get an additional booster in the fall."

By Jordan Schachtel
Global Research, April 01, 2022
The Dossier 31 March 2022
Region:
Theme:

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), click here.

Visit and follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

***

On the same day that the FDA authorized a fifth mRNA COVID injection for immunocompromised individuals (and a fourth for the general population over 50), one of the FDA’s top bureaucrats is already projecting more mRNA doses to come.

“I don’t want to shock anyone, but there may be a need for people to get an additional booster in the fall,” Peter Marks, the director of the FDA’s Center for Biologic Evaluation and Research, told reporters.

For mRNA compliant citizens, that round of shots would mark a fifth or sixth injection of a non FDA-approved experimental mRNA vaccine — which can cause significant side effects with each additional dose for some — within a two year window.

Marks explained that an FDA advisory committee will discuss the probability of another mRNA dose next week. That committee was supposed to meet before the latest booster authorization to evaluate the safety and efficacy of a fourth and fifth round of shots. The FDA decided to bypass that process entirely.

“It’s not actually clear yet what the optimal booster should be,” Marks said. “We’re hoping by taking this action, we will help allow people to take steps to protect themselves should we have another wave to come through this country.”

He added that the next dose might be one that is reformulated for a more current variant, but did not commit one way or another.

The current mRNA shot was designed by both Pfizer and Moderna to target the ostensibly original Wuhan strain of 2019. This strain no longer exists in circulation, and according to gene sequencing, it has not been the dominant strain for about two years. The 2019 shot has never been updated, despite claims of an update being as easy as a computer-generated “copy and paste” procedure. Pfizer and Moderna both claimed that they were working on an Omicron vaccine — projecting that it would be ready in March of 2022 — but seem to have scrapped the plan, for reasons unknown to the public.

The U.S. government has already spent tens of billions of dollars in taxpayer funds to enrich Pfizer and Moderna, which seem to have assumed full regulatory capture of Government Health agencies. These agencies now deliver timely rubber stamp approvals for their latest experimental products, and they routinely dismiss the overwhelming evidence of a negative efficacy, failed vaccine program.

On Wednesday, President Biden got his claimed “second booster” (fourth injection) on live television, marking the president’s fourth shot in the last 15 months.

He then demanded more money from taxpayers to finance future doses for “new variants.”

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

Featured image is from Children’s Health Defense
Articles by: Jordan Schachtel

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]